Overview

Urokinase (CAS 9039-53-6) is a serine protease enzyme widely used as a thrombolytic agent for dissolving blood clots. Manufactured according to In-House, IP, EP, and BP standards, it is a critical tool in managing acute ischemic stroke, pulmonary embolism, deep vein thrombosis (DVT), and other thrombotic disorders. Its precise clot-lysing action makes it invaluable in emergent and interventional therapies.

Key Applications

• Acute Ischemic Stroke: Restores blood flow in blocked brain arteries, minimizing neurological damage.
• Pulmonary Embolism: Dissolves lung clots, preventing complications such as right heart strain or cardiac arrest.
• Peripheral Arterial Thrombosis: Restores circulation in limb arteries, reducing tissue damage or limb loss.
• Deep Vein Thrombosis (DVT): Catheter-directed thrombolysis rapidly restores venous flow.
• Central Venous Catheter Occlusion: Clears thrombotic blockages, maintaining catheter patency.
• Acute Myocardial Infarction: Dissolves coronary thrombi to restore heart muscle blood flow (less common than tPA).
• Renal Vein Thrombosis: Promotes clot lysis, preserving kidney function and alleviating congestion.
• Other Thrombotic Disorders: Explored in acute limb ischemia, mesenteric artery thrombosis, and other occlusive vascular diseases.

Summary

Urokinase remains a highly valuable thrombolytic enzyme, offering precise and effective clot dissolution across a wide spectrum of thrombotic conditions. Its role in emergent care and interventional catheter-directed therapies makes it an essential agent in contemporary clinical practice.